Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer

被引:5
作者
Jeon, Seung Hyuck [1 ]
Kim, So-Woon [2 ]
Na, Kiyong [2 ]
Seo, Mirinae [3 ]
Sohn, Yu-Mee [3 ]
Lim, Yu Jin [4 ]
机构
[1] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea
[2] Kyung Hee Univ Coll Med, Kyung Hee Univ Med Ctr, Dept Pathol, Seoul, South Korea
[3] Kyung Hee Univ Coll Med, Kyung Hee Univ Med Ctr, Dept Radiol, Seoul, South Korea
[4] Kyung Hee Univ Coll Med, Kyung Hee Univ Med Ctr, Dept Radiat Oncol, Seoul, South Korea
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
新加坡国家研究基金会;
关键词
immunophenotype; CD8+T cells; radiomics; breast cancer; magnetic resonanace imaging; CHEMOTHERAPY;
D O I
10.3389/fimmu.2022.1080048
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infiltration of CD8(+) T cells and their spatial contexture, represented by immunophenotype, predict the prognosis and therapeutic response in breast cancer. However, a non-surgical method using radiomics to evaluate breast cancer immunophenotype has not been explored. Here, we assessed the CD8(+) T cell-based immunophenotype in patients with breast cancer undergoing upfront surgery (n = 182). We extracted radiomic features from the four phases of dynamic contrast-enhanced magnetic resonance imaging, and randomly divided the patients into training (n = 137) and validation (n = 45) cohorts. For predicting the immunophenotypes, radiomic models (RMs) that combined the four phases demonstrated superior performance to those derived from a single phase. For discriminating the inflamed tumor from the non-inflamed tumor, the feature-based combination model from the whole tumor (RM-whole(FC)) showed high performance in both training (area under the receiver operating characteristic curve [AUC] = 0.973) and validation cohorts (AUC = 0.985). Similarly, the feature-based combination model from the peripheral tumor (RM-peri(FC)) discriminated between immune-desert and excluded tumors with high performance in both training (AUC = 0.993) and validation cohorts (AUC = 0.984). Both RM-whole(FC) and RM-peri(FC) demonstrated good to excellent performance for every molecular subtype. Furthermore, in patients who underwent neoadjuvant chemotherapy (n = 64), pre-treatment images showed that tumors exhibiting complete response to neoadjuvant chemotherapy had significantly higher scores from RM-whole(FC) and lower scores from RM-peri(FC). Our RMs predicted the immunophenotype of breast cancer based on the spatial distribution of CD8(+) T cells with high accuracy. This approach can be used to stratify patients non-invasively based on the status of the tumor-immune microenvironment.
引用
收藏
页数:12
相关论文
共 43 条
  • [1] Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software
    Berben, Lieze
    Wildiers, Hans
    Marcelis, Lukas
    Antoranz, Asier
    Bosisio, Francesca
    Hatse, Sigrid
    Floris, Giuseppe
    [J]. HISTOPATHOLOGY, 2020, 77 (01) : 79 - 91
  • [2] Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics
    Bian, Tiantian
    Wu, Zengjie
    Lin, Qing
    Mao, Yan
    Wang, Haibo
    Chen, Jingjing
    Chen, Qianqian
    Fu, Guangming
    Cui, Chunxiao
    Su, Xiaohui
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2022, 55 (03) : 772 - 784
  • [3] Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
    Braman, Nathaniel M.
    Etesami, Maryam
    Prasanna, Prateek
    Dubchuk, Christina
    Gilmore, Hannah
    Tiwari, Pallavi
    Pletcha, Donna
    Madabhushi, Anant
    [J]. BREAST CANCER RESEARCH, 2017, 19
  • [4] Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
    Brown, Jason R.
    Wimberly, Hallie
    Lannin, Donald R.
    Nixon, Christian
    Rimm, David L.
    Bossuyt, Veerle
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5995 - 6005
  • [5] Tissue-resident memory T cells in breast cancer control and immunotherapy responses
    Byrne, Ann
    Savas, Peter
    Sant, Sneha
    Li, Ran
    Virassamy, Balaji
    Luen, Stephen J.
    Beavis, Paul A.
    Mackay, Laura K.
    Neeson, Paul J.
    Loi, Sherene
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (06) : 341 - 348
  • [6] Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases
    Cheung, Ben Man Fei
    Lau, Kin Sang
    Lee, Victor Ho Fun
    Leung, To Wai
    Kong, Feng-Ming Spring
    Luk, Mai Yee
    Yuen, Kwok Keung
    [J]. RADIATION ONCOLOGY JOURNAL, 2021, 39 (04): : 254 - 264
  • [7] Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9
  • [8] Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy
    Dieci, Maria Vittoria
    Tsvetkova, Vassilena
    Griguolo, Gaia
    Miglietta, Federica
    Tasca, Giulia
    Giorgi, Carlo Alberto
    Cumerlato, Enrico
    Massa, Davide
    Mele, Marcello Lo
    Orvieto, Enrico
    Guarneri, Valentina
    Conte, Pierfranco
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 136 : 7 - 15
  • [9] Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
    Emens, Leisha A.
    Molinero, Luciana
    Loi, Sherene
    Rugo, Hope S.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Barrios, Carlos H.
    Nechaeva, Marina
    Anh Nguyen-Duc
    Chui, Stephen Y.
    Husain, Amreen
    Winer, Eric P.
    Adams, Sylvia
    Schmid, Peter
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08): : 1005 - 1016
  • [10] Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
    Emens, Leisha A.
    Cruz, Cristina
    Eder, Joseph Paul
    Braiteh, Fadi
    Chung, Cathie
    Tolaney, Sara M.
    Kuter, Irene
    Nanda, Rita
    Cassier, Philippe A.
    Delord, Jean-Pierre
    Gordon, Michael S.
    ElGabry, Ehab
    Chang, Ching-Wei
    Sarkar, Indrani
    Grossman, William
    O'Hear, Carol
    Fasso, Marcella
    Molinero, Luciana
    Schmid, Peter
    [J]. JAMA ONCOLOGY, 2019, 5 (01) : 74 - 82